Denali Therapeutics Inc. DNLI

NASDAQHealth TechnologyUnited States

$18.74-0.15 (-0.79%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 18.3418.91
52-week range: 15.3427.30

Financial health

– / 5

Analyst view · 21 firms

Buy20 buy · 1 hold · 0 sell

Avg. target $35.82 (+91.2%)

Prices may be delayed and are for informational purposes only - not investment advice.

Denali Therapeutics Inc. DNLI

NASDAQHealth TechnologyUnited States

$18.74-0.15 (-0.79%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 18.3418.91
52-week range: 15.3427.30

Financial health

– / 5

Analyst view · 21 firms

Buy20 buy · 1 hold · 0 sell

Avg. target $35.82 (+91.2%)

Valuation from filings

Calculated from the tables below and the current price ($18.74) · LTM · 2026/9 · 2026-09-30

P/E: —EPS $-1.73
P/B: 3.82BV/share $4.91
P/S: 165.36Sales/share $0.11
Return on equity: -33.9%Net income / equity
Net margin: -1,470.5%Operating margin -2,488.1%
Free cash flow yield: -15.0%Free cash flow / market cap

Revenue and net income

Fiscal year · $ millions · net margin below

RevenueNet Income

Financial statements

$ thousands · Under each value: change against a year earlier

Upgrade to MakklerPRO to see every row.Upgrade to MakklerPRO

Fiscal year	2021	2022	2023	2024	2025	LTM
Income Statement
Revenue	48,661	108,463+123%	330,531+205%	0–	0–	21,382
Operating expenses
Operating Income
EBITDA
Income tax (expense) / benefit
Net Income	(290,581)	(325,991)+12%	(145,224)-55%	(422,773)+191%	(512,540)+21%	(314,423)
Earnings per share ($)
Margins
Operating margin
EBITDA margin
Net margin

Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.